Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Gilead Sciences is paying $300 million for a 49.9% stake in San Francisco–based Tizona Therapeutics. The centerpiece of the deal is TTX-080, an antibody that targets the immune checkpoint protein HLA-G; it is expected to begin clinical studies in solid cancers this quarter. Gilead can acquire the rest of the firm for up to $1.25 billion after seeing data from Phase Ib studies. The deal does not include TTX-030, an anti-CD39 antibody that Tizona licensed to AbbVie for $105 million last year.
This article has been sent to the following recipient: